Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Alikhan, Raza ^a   Bedenis, Rachel ^b   Cohen, Alexander T ^c  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; ANTICOAGULANT AGENT;

ACUTE DISEASE; ALL CAUSE MORTALITY; BLEEDING; BRAIN HEMORRHAGE; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; EPIDURAL HEMATOMA; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HEMATURIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INJECTION SITE BLEEDING; INTRAOCULAR HEMORRHAGE; LOW DRUG DOSE; LUNG EMBOLISM; MELENA; PETECHIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL HEMORRHAGE; REVIEW; SPINAL HEMATOMA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; META ANALYSIS; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

ACUTE DISEASE; ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84990008233     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003747.pub4     Document Type: Review

References (98)

1. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low dose heparin. Scottish Medical Journal 1981;26(2):115-7.
2. Belch JJF, Lowe GDO, Ward AG, Forbes CD, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low dose subcutaneous heparin. Thrombosis and Haemostasis 1981;46(1):379-Abstract No.1187.
3. Bergmann JF, Caulin C. Heparin prophylaxis in bedridden patients. Lancet 1996;348(9021):205-6.
4. Mahe I, Bergmann JF, d'Azemar P, Vaissie JJ, Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. European Journal of Clinical Pharmacology 2005;61(5-6):347-51.
5. Anon. Efficacy and safety of low-molecular weight heparin for thromboprophylaxis in acutely ill medical patients. ClinicalTrials.gov NCT00311753 2010.
6. Schellong SM, Haas S, Greinacher A, Schwanebeck U, Sieder C, Abletshauser C, et al.An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opinion on Pharmacotherapy 2010;11(18):2953-61.
7. Anon. A comparison of certoparin and unfractionated heparin in the prevention of thromboembolic events in acutely ill medical patients. ClinicalTrials.gov NCT00451412 2007.
8. Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, et al.CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Hamostaseologie 2011;31(1):A5.
9. Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, et al.CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis 2011;105(6):981-8.
10. Haas S, Schellong SM, Tebbe U, Gerlach H-E, Bauersachs R, Abletshauser C, et al.CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. Hamostaseologie 2011;31(1):A10.
11. Haas S, Schellong SM, Tebbe U, Gerlach H-E, Bauersachs R, Melzer N, et al.Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. BMC Cancer 2011;11:316.
12. Riess H, Haas S, Tebbe U, Gerlach H, Abletshauser C, Sieder C, et al.CERTIFY - Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, medical patients: A randomized, double-blind, multicentre study. Onkologie 2010;33(6):51-2.
13. Riess H, Haas S, Tebbe U, Gerlach H-E, Abletshauser C, Sieder C, et al.A randomized, double-blind, multicenter study of Certoparin versus UFH to prevent venous thromboembolic events in acutely ill, hospitalized, non-surgical patients: the CERTIFY study. Hamostaseologie 2010;30(1):A21.
14. Riess H, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, et al.A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. Journal of Thrombosis and Haemostasis 2010;8(6):1209-15.
15. Schellong SM, Gerlach H-E, Tebbe U, Haas S, Abletschauser C, Sieder C, et al.CERTIFY: Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient. Hamostaseologie 2011;31(1):A87.
16. Schellong SM, Gerlach HE, Tebbe U, Haas S, Melzer N, Abletshauser C, et al.Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thrombosis Research 2011;128(5):417-21.
17. Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C, et al.Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study. American Heart Journal 2011;161(2):322-8.
18. Dahan R, Fauchet M, Houlbert D, Caulin C, Segrestaa JM. [Prevention of isotopic veinous thrombosis (IVT) in elderly patients using a low molecular weight heparin (LMWH): a double-blind clinical trial]. Therapie 1986;41:522-3.
19. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, et al.Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomised double blind trial. Haemostasis 1986;16(2):159-64.
20. Dahan R, Houlbert D, Caulin D, Segresta MM, et al.Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin (enoxaparin): randomized double blind trial. Thrombosis and Haemostasis 1985;54(1):309-Abstract No SS36.
21. Bergmann JF, Neuhart E. A multicenter randomised double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thrombosis and Haemostasis 1996;76(4):529-34.
22. Bergmann JF, for the Geriatric Enoxaparin Study Group, France. Prevention of venous thromboembolism in elderly medical in-patients: a double blind comparative study of unfractionated heparin (2 x 5000 IU) and enoxaparin (20 mg). Annals of Hematology 1994;68 Suppl 1:A90.
23. Forette B, Wolmark Y. Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects. Presse Medicale 1995;24(12):567-71.
24. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, et al.Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. American Journal of Respiratory Critical Care Medicine 2000;161(4 Pt1):1109-14.
25. Gallus AS, Hirsh J, Tuttle RJ, Treblicock R, O'Brien SE, Carroll JJ, et al.Small subcutaneous doses of heparin in prevention of venous thrombosis. New England Journal of Medicine 1973;288(11):545-51.
26. Gardlund B for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996;347:1357-61.
27. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, Arévila-Ceballos N, Fong JH, Sánchez-Martínez R, et al.Prevalence and prevention of deep vein thrombosis of the lower extremities in high risk pulmonary patients. Angiology 1988;39(6):505-13.
28. Anon. Study to evaluate the mortality reduction of enoxaparin in hospitalized acutely ill medical receiving enoxaparin (LIFENOX). ClinicalTrials.gov NCT00622648 2010.
29. Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergman J-F, for the LIFENOX Investigators. Low molecular weight heparin and mortality in acutely ill medical patients. New England Journal of Medicine 2011;365(26):2463-72.
30. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al.Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation and Fibrinolysis 2003;14(4):341-6.
31. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al.MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Archives of Internal Medicine 2004;164(9):963-8.
32. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Olson C-G, et al.Benefit of enoxaparin in medical patients: A subgroup analysis. Blood 2001;98(11):266A.
33. Amin AN, Girard F, Samama MM. Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis 2010;104(5):955-61.
34. Cohen AT, Zaw HM, Alikhan R. Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial. Seminars in Hematology 2001;38(2 Suppl 5):31-8.
35. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al.A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine 1999;341(11):793-800.
36. Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. American Journal of Cardiology 2000;86(12B):48M-52M.
37. Leizorovicz A, Cohen A, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ. A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely ill medical patients: the PREVENT medical thromboprophylaxis study. Journal of Thrombosis and Haemostasis 2003;1 Suppl 1:Abstract OC 396.
38. Leizorovicz A, Cohen AT, Turpie AG, Olsson C-G, Vaitkus PT, Weitz JI, et al.Efficacy and safety of combining dalteparin with aspirin in preventing venous thromboembolism in medical patients. Blood 2003;102(11):Abstract 1153.
39. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110(7):874-9.
40. Vaitkus PT, Leizorovicz A, Goldhaber SZ, Olsson CG, Cohen AT, Weitz JI, et al.Mortality is increased in patients with proximal, but not distal, deep vein thrombosis in medically ill patients entered in the PREVENT trial. Blood 2003;102(11):165a.
41. Vaitkus PT, Leizorovicz A, Goldhaber SZ, PREVENT Investigator Group. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study). Vascular Medicine 2002;7(4):269-73.
42. Keller F, Flosbach CW, THE PRIME - Study Group. A randomised multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised medical patients. Thrombosis and Haemostasis 1995;73(6):1106-Abstract No 788.
43. Lechler E, Schramm W, Flosbach CW. A randomized, multicentre double blind study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilised patients. Annals of Hematology 1994;68 Suppl 1:A55.
44. Lechler E, Schramm W, Flosbach CW, The PRIME Study Group. The venous thrombotic risk in nonsurgical patients: Epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). Haemostasis 1996;26 Suppl 2:49-56.
45. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. American Heart Journal 2003;145(4):614-21.
46. Aquino JP, Gambier A, Ducros J. Prevention of thromboembolic accidents in elderly subjects with fraxiparine. In: Bounameaux H, Samama MM, Ten Cate JW editor(s). Fraxiparine, Second International Symposium Recent Pharmacological and Clinical Data. New York: Schattauer, 1990:51-4.
47. Cade JF. High risk of the critically ill for venous thromboembolism. Critical Care Medicine 1982;10(7):448-50.
48. Cade JF, Andrews JT, Stubbs AE. Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Australian and New Zealand Journal of Medicine 1982;12(5):501-4.
49. Hull R, Schellong S, Tapson V, Yusen R, Monreal M, Samama MM, et al.Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study. Journal of Thrombosis and Haemostasis 2003;1 Suppl 1:Abstract OC397.
50. Hull R, Tapson VF, Schellong S, Yusen RD, Monreal M, Samama MM, et al.The EXCLAIM Study: Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with restricted mobility. Blood 2003;102(11 (Part 2)):1-514.
51. Hull RD, Schellong S, Tapson V, Yusen R, Monreal M, Samama MM, et al.Extended thromboprophylaxis in acutely ill medical patients with prolonged immobilisation: The EXCLAIM study. Blood 2002;100(11):Abstract 3988.
52. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, et al.EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Annals of Internal Medicine 2010;153(1):8-18.
53. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AG, et al.Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. Journal of Thrombosis and Thrombolysis 2006;22(1):31-8.
54. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AGG, et al.Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: The EXCLAIM study. XXIst Congress of the International Society of Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva. 2007.
55. Schellong SM, Hull RD, Tapson VF, Monreal M, Samama MM, Turpie AGG, et al.Extended-duration enoxaparin for venous thromboembolism prophylaxis in acutely ill medical patients: an evaluation of the EXCLAIM study based on a recently recommended composite efficacy endpoint. Blood 2007;110(11):554a.
56. Tapson VF, Hull RD, Schellong SM, Monreal M, Samama MM, Turpie AGG, et al.Consistent venous thromboembolism risk reduction by extended- versus standard-duration enoxaparin prophylaxis in subgroups of acutely ill medical patients in the EXCLAIM study. Blood 2007;110(11):552a.
57. Yusen RD, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, et al.The effects of the degree of mobility reduction and prespecified risk factors on venous thromboembolism rates in acutely ill medical patients in the EXCLAIM study. Blood 2007;110(11):551a.
58. Yusen RD, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, et al.The impact of age on the efficacy and safety of extended-duration thromboprophylaxis in acutely ill medical patients with recent immobility: a sub-group analysis from the EXCLAIM Study. ASH 2009; Vol. 112, issue 11:167.
59. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low dose heparin prophylaxis. Annals of Internal Medicine 1982;96(5):561-5.
60. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, et al.Randomised controlled study of heparin and low molecular weight heparin for prevention of deep vein thrombosis in medical patients. Thrombosis Research 1990;59(3):639-50.
61. Harenberg J, Roebruck P, Heene DL, HESIM Group. Prevention of thromboembolism in medical inpatients. Haemostasis 1994;24 Suppl 1:36-Abstract No 36.
62. Harenberg J, Roebruck P, Stehle G, Habscheid W, Biegholdt M, Heene DL. Heparin Study in Internal Medicine (HESIM): design and preliminary results. Thrombosis Research 1992;68(1):33-43.
63. Harenburg J, Roebruck P, Heene DL. Subcutaneous low molecular weight heparin versus standard heparin and the prevention of thromboembolism in medical patients. The Heparin Study in Internal Medicine (HESIM). Haemostasis 1996;26(3):127-39.
64. Manciet G, Vergnes C, Vaissie JJ, Boisseau MR. A study of the efficacy and tolerance of fraxiparine during long term therapy of the elderly. A randomized double-blind clinical trial. In: Bounameaux H, Samama MM, Ten Cate JW editor(s). Fraxiparine Second International Symposium. Recent Pharmacological and Clinical Data. New York: Schattauer, 1990:55-9.
65. Mottier D. Prophylaxis of deep vein thrombosis in medical geriatric patients. Thrombosis and Haemostasis 1993;69(6):1115-Abstract No. 2045.
66. Poniewierski M, Barthels M, Kuhn M, Poliwoda H. Efficacy of low molecular weight heparin (Fragmin) for thromboprophylaxis in medical patients: A randomized double blind trial [Uber die Wirkamkeit niedermolekularen Heparins (Fragmin) in der Thromboembolieprophylaxe bei internistischen Patienten]. Medizinische Klinische 1988;83(7):241-5.
67. Lederle FA, Sacks JM, Fiore L, Landefeld CS, Steinberg N, Peters RW, et al.The prophylaxis of medical patients for thromboembolism pilot study. American Journal of Medicine 2006;119(1):54-9.
68. Veterans Administration. Prophylaxis of medical patients for thromboembolism (PROMPT) study. Veterans Administration Office of Research and Development New Initiatives: Meeting Veterans Needs 1999:3.
69. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al.ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. New England Journal of Medicine 2011;365(23):2167-77.
70. Ageno W, Spyropoulos AC, Turpie AGG. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. Thrombosis and Haemostasis 2012;107(6):1027-34.
71. Alikhan R, Wilmott R, Agrawal S, Desouza N, Gera A, Zaw H, et al.Use of thromboprophylaxis in non-surgical patients: survey of a London teaching hospital. Blood 2001;98(11):271.
72. Alikhan R, Peters F, Wilmott R, Cohen A. Fatal pulmonary embolism in hospitalised patients: - a necropsy review. Journal of Clinical Pathology 2004;57(12):1254-7.
73. Bump GM, Dandu M, Kaufman SR, Shojania KG, Flanders SA. How complete is the evidence for thromboembolism prophylaxis in general medicine patients? A meta-analysis of randomized controlled trials. Journal of Hospital Medicine 2009;4(5):289-97.
74. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis 1996;26(2):65-71.
75. Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al.for the ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371(9610):387-94.
76. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. New England Journal of Medicine 1988;318(18):1162-73.
77. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al.Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996;313(7058):652-9.
78. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008;112(1):19-27.
79. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalised medical patients. Annals of Internal Medicine 2007;146(4):278-88.
80. Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AWS. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008500.pub2].
81. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24S-e43S.
82. Geets WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, et al.Prevention of venous thromboembolism. Chest 2001;119:132S.
83. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al.Prevention of venous thromboembolism. Chest 2008;133(6 Suppl):381S-453S.
84. Gubitz G, Sandercock P, Counsell C. Anticoagulants for acute ischaemic stroke (Review). Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000024.pub2].
85. House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. London: The Stationery Office Ltd, 2005.
86. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
87. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
88. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al.American College of Chest Physicians. Prevention of VTE in non surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e195S-226S.
89. Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: A background review for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine 2011;155(9):602-15.
90. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, et al.for the MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. New England Journal of Medicine 2013;368(6):513-23.
91. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al.Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: a meta-analysis of randomised clinical trials. Thrombosis and Hemostasis 2000;83(1):14-9.
92. Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, et al.RIETE Investigators. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. Journal of Thrombosis and Haemostasis 2004;2(11):1892-8.
93. National Institute for Health and Care Excellence (NICE). Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital, Clinical guidelines CG92. NICE 2010:http://guidance.nice.org.uk/CG92.
94. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. Journal of the Royal Society of Medicine 1989;82(4):203-5.
95. Song Y, Liu L, Li X, Ding J. Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD005134.pub2].
96. Wille-Jørgensen P, Rasmussen MS, Andersen BR, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery (Review). Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD001217].
97. Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD003747.pub2].
98. Alikhan R, Cohen AT. Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD003747.pub3].